News & Perspective

Sep 09, 2008

Sep 09, 2008

HHS funds work on new anthrax antitoxin

(CIDRAP News) – Emergent BioSolutions Inc. recently announced that it won a federal contract worth $24.3 million to develop a monoclonal antibody treatment to block the effects of anthrax toxin.